Glaukos's (GKOS) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Glaukos Corp  (NYSE: GKOS)
 



  Glaukos Corp Outlook

On January 9 2024 the Glaukos Corp provided following guidance

Based on the latest information, Glaukos Corporation (NYSE: GKOS) has announced its preliminary, unaudited net sales for the fourth quarter and full year of 2023. The company, which specializes in ophthalmic medical technology and pharmaceuticals for the treatment of glaucoma, corneal disorders, and retinal diseases, anticipates total net sales of over $81 million for the fourth quarter and over $313 million for the full year ended December 31, 2023.

This announcement reaffirms Glaukos' 2024 revenue guidance, demonstrating the company's confidence in its future financial performance. As an innovative provider of therapies in the ophthalmic field, Glaukos continues to make significant progress in addressing the needs of patients with various eye conditions.

Please note that these figures are preliminary and unaudited, subject to potential adjustments during the final audit process. Nonetheless, Glaukos' strong net sales indicate its success in delivering effective solutions to the market, solidifying its position as a leader in ophthalmic medical technology and pharmaceuticals.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.